Literature DB >> 7074652

Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin's disease.

P Mauch, D Gorshein, J Cunningham, S Hellman.   

Abstract

Between April 1969 and July 1979, 267 patients with surgically staged IA-IIB Hodgkin's disease and 31 with clinically staged IIE or IV Hodgkin's disease were treated; disease was limited to the area above the diaphragm. Three separate groups of patients with mediastinal adenopathy were identified. Patients with disease limited to the mediastinum had a favorable prognosis, and treatment with mantle followed by para-aortic irradiation has resulted in 85% relapse-free survival and 100% overall survival at 8 years. Surgically staged patients with large diameter mediastinal adenopathy (greater than 0.33 of the thoracic diameter) have a high relapse rate with radiation therapy alone. The use of combined modality therapy has reduced the risk of relapse in these patients, but the survival remains higher whether MOPP is used initially or at relapse. Clinically staged IIE patients or stage IV patients with extensive extranodal disease limited to the thoracic cavity were treated with chemotherapy and involved- or extended-field irradiation. These patients had a 5-year survival of 66% with large mediastinal adenopathy and 90% with lesser mediastinal disease.

Entities:  

Mesh:

Year:  1982        PMID: 7074652

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  6 in total

1.  Superior vena cava syndrome caused by Hodgkin's lymphoma in an adolescent girl.

Authors:  Imran Rizvi; Shamsuz Zaman; Noorin Zaidi; Syed Mohammad Kamil Ashraf; Arun Kumar; Ankush Gupta; Mehtab Ahmad
Journal:  BMJ Case Rep       Date:  2012-02-21

2.  Radiation therapy alone versus radiation therapy and chemotherapy in the management of Hodgkin's disease.

Authors:  L D Glenn; P P Kumar
Journal:  J Natl Med Assoc       Date:  1990-02       Impact factor: 1.798

Review 3.  Current management of Hodgkin's disease.

Authors:  B C Behrens; R C Young; V T DeVita
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

Review 4.  Extended-field isocentric irradiation for Hodgkin's disease.

Authors:  P P Kumar; R R Good; E O Jones; J E Somers; B E McAnulty; G F McCaul; S S Rogers; M A Reeves; C K Sanders
Journal:  J Natl Med Assoc       Date:  1987-09       Impact factor: 1.798

5.  Staging laparotomy with splenectomy for Hodgkin's disease: the Stanford experience.

Authors:  M A Taylor; H S Kaplan; T S Nelsen
Journal:  World J Surg       Date:  1985-06       Impact factor: 3.352

6.  Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy.

Authors:  L Specht; A M Nordentoft; S Cold; N T Clausen; N I Nissen
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.